Recent Updates
Recently added Catalysts
TLSI Positive Sentiment Score: 70/100

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Key Takeaway: TriSalus Life Sciences will participate in the Canaccord Genuity 46th Annual Growth Conference, featuring CEO Mary Szela and CFO David Patience. The event will include one-on-one meetings, highlighting the company's commitment to oncology and investor engagement. This participation reflects the company's ongoing efforts to enhance its visibility in the biopharma sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent growth conference
  • Opportunity for one-on-one meetings with investors
  • Showcases company leadership and strategic vision

Full Press Release Details

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings o

Frequently Asked Questions

Who will represent TriSalus at the conference?

Mary Szela, CEO, and David Patience, CFO, will represent TriSalus.

What is the purpose of the Canaccord Genuity conference?

The conference aims to facilitate investor engagement and showcase company strategies.

What type of meetings will TriSalus conduct at the event?

TriSalus will participate in one-on-one meetings with investors.

Last updated: Jul 29, 2026